Abstract:
Triple Negative Breast cancer (TNBC) is a heterogeneous disease that is oestrogen receptor,
progesterone receptor, and human epidermal growth factor receptor 2 negative
based on immunohistochemistry. TNBC is distinguished by a specific molecular profile,
aggressiveness, and a lack of targeted treatment. Some of the patients that have undergone
treatment tend to relapse after a certain time period due to distant metastasis.
Therapies already being used to treat TNBC include chemotherapy, targeted therapy,
surgery, and radiation therapy. However, TNBC develops resistance to certain therapies
over time and results in ineffective treatment. Therefore, no proper treatment is available
and research needs to be done on finding new targets for drug manufacturing. In
this study, we have performed RNA Sequencing analysis through Galaxy and Ballgown
on two data sets of TNBC in order to determine differentially expressed genes that could
be used as targets for the cancer. Then, we performed a comparative analysis to determine
the common DEGs among the data sets. After this we performed pathway analysis
of these DEGs using reactome, to discover targetable pathways. We found seven differentially
expressed genes and ten targettable pathways. The common genes that can be
targetted to treat the TNBC cancer included DDIT4, DYRK3, ELF3, H2BC21, JUN,
LEPROT,and RPL21P16. The most enriched and significant pathways include Pre-
NOTCH Transcription, Translation, Expression and Processing, Signaling by NOTCH,
programmed cell death, Senescence-Associated Secretory Phenotype (SASP), Oxidative
Stress Induced Senescence,HOX gene activation in Hindbrain development and differentiation,
transcription and estrogen dependant gene expression.
